- Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery, development, regulatory, and sales milestones along with royalties on net sales of products
- During the 3-yr collaboration, Artios and Novartis will discover and validate up to three exclusive DDR targets and receive WW rights on these targets with its RLT’s
- The collaboration does not include Artios’ lead programs (ART0380 and ART4215), currently under clinical development
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Artios Pharma
The post Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies first appeared on PharmaShots.